Top Story Today
CAR-T's Autoimmune Gold Rush Just Slammed Into a Wall
Three patient deaths from a severe immune reaction forced Novartis to freeze all eight of its autoimmune CAR-T trials, covering eight different diseases from lupus to multiple sclerosis. Days later, Bristol Myers Squibb paused enrollment in its own autoimmune CAR-T program for similar safety concerns. Two of the world's biggest pharma companies hitting the brakes on the same therapy, in the same month, isn't a coincidence; it's a pattern that could reshape the entire field. The fundamental problem: autoimmune patients aren't terminal cancer patients, and even a small risk of death from the treatment itself becomes very hard to justify.
Why it matters: The safety crisis forces a field-wide reckoning over whether powerful immune-cell therapies can ever achieve an acceptable risk-benefit ratio in non-cancerous diseases, threatening to derail what was biotech's most hyped new frontier.
Read more →Clinical and Regulatory
Tagrisso's $7 Billion Fortress Just Got Reinforcements
AstraZeneca's Phase III SAFFRON trial showed that combining Tagrisso with Hutchmed's Orpathys extended both progression-free and overall survival in EGFR-mutant lung cancer patients whose tumors developed resistance. It's the first global Phase III to prove a targeted combo works in this setting, and it keeps Tagrisso at the center of treatment as J&J's rival combo circles.
Read more →GSK's mRNA Flu Vaccine Beat Standard Shots. Now the Real Test Begins.
GSK's mRNA flu vaccine outperformed traditional shots on immune response in Phase 2 and is heading to a pivotal Phase 3 trial in September 2026. The catch: another mRNA flu program previously hit strong antibody numbers but failed to prevent more actual flu cases in Phase 3. Better antibodies don't always equal better protection.
Read more →Relaxin, the Comeback Kid of Heart Failure, Returns as a Daily Pill
AstraZeneca turned relaxin (a target that failed spectacularly as an IV drip under Novartis) into an oral pill called AZD5462. Phase 2 data from 375 patients showed meaningful cardiac remodeling and vascular improvements with a clean safety profile. The weird wrinkle: the lowest dose worked best, creating a puzzle AstraZeneca must solve before Phase 3.
Read more →The FDA Commissioner Tried to Block a Drug. Career Scientists Said No.
FDA Commissioner Marty Makary reportedly pushed staff to reject KalVista's rare disease drug sebetralstat, only to have career scientists warn the move would be "arbitrary and capricious" under the law. The drug was eventually approved in July 2025. The episode is the clearest example yet of alleged political interference in FDA decision-making.
Read more →Deals and Business
Samsung Biologics Bets $1.8 Billion That Peptides Are the Future
Samsung Biologics filed a tender offer to acquire Swiss peptide manufacturer PolyPeptide Group for roughly $1.8 billion in cash, a direct play on insatiable GLP-1 manufacturing demand. PolyPeptide's revenue grew 15.6% last year, its board unanimously recommended the deal, and Samsung plans to delist the company entirely. The CDMO consolidation wave keeps rolling.
Read more →The Drug Pricing Squeeze Just Reached Midsize Biotech
Nine midsize drug companies (including BridgeBio, Teva, and CSL) signed MFN pricing deals with the Trump administration, trading lower U.S. drug prices for concessions. Unlike Big Pharma giants with deep portfolios, smaller companies have far less room to absorb margin hits. Wall Street shrugged for now, but the structural pressure is compounding one deal at a time.
Read more →Sanofi-Backed Electra Files for a $100 Million Nasdaq IPO
Electra Therapeutics filed its S-1 to go public, armed with Phase 1b data showing 100% survival at eight weeks in a disease where half of patients on standard treatment typically die. The Sanofi-backed biotech holds FDA Breakthrough Therapy designation and is running a pivotal Phase 2/3 trial, making it a test case for fall 2026's IPO window.
Read more →IP and Legal
A $4.8 Million Patent Verdict Could Reshape Single-Cell Sequencing
A Delaware jury found Parse Biosciences willfully infringed three sequencing patents licensed by Roche to a 10x Genomics unit, awarding $4.8 million at a 14% royalty rate. The real threat: 10x is now seeking enhanced damages (potentially tripling the award) and a permanent injunction that could force Parse to pull its flagship Evercode product line from the market.
Read more →